We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
신규 편입 · 포트폴리오 비중 0.03%
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $32.25 · 5 analysts
Stored first · Google News · Yahoo Finance (English)
New Options Listings Include Aktis Oncology Inc (AKTS) - GuruFocus
New Options Listings Include Aktis Oncology Inc (AKTS) GuruFocus
AKTS Maintained by JP Morgan -- Price Target Raised to $33.00 - GuruFocus
AKTS Maintained by JP Morgan -- Price Target Raised to $33.00 GuruFocus
JPMorgan Chase & Co. Increases Aktis Oncology (NASDAQ:AKTS) Price Target to $33.00 - MarketBeat
JPMorgan Chase & Co. Increases Aktis Oncology (NASDAQ:AKTS) Price Target to $33.00 MarketBeat
Price to book forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Price to book forward of Aktis Oncology, Inc. – NASDAQ:AKTS TradingView
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Analysts MarketBeat
Aktis Oncology COO Ron-Bigger sells $1.39m in shares - Investing.com UK
Aktis Oncology COO Ron-Bigger sells $1.39m in shares Investing.com UK
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 11. | After market close (AMC) | $-0.48 | — | — | $3.33M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-18.6 | — | — | $1.45M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 29. | William Blair | — | Initiate coverage | — → Outperform | — | William Blair: Outperform |
| 2026. 03. 31. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 03. 09. | HC Wainwright & Co. | — | Initiate coverage | — → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 02. 03. | Leerink Partners | — | Initiate coverage | — → Outperform | — | Leerink Partners: Outperform |
| 2026. 02. 03. | JP Morgan | — | Initiate coverage | — → Overweight | — | JP Morgan: Overweight |
| 2024. 01. 04. | Piper Sandler | — | Downgrade | Overweight → Neutral | — | Piper Sandler: Overweight → Neutral |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | SOROS FUND MANAGEMENT LLC | SOROS FUND MANAGEMENT LLC | 100,000 | $1.79M | 0.03% | — | New position |